4baseCare Launches Targt Indiegene® V2, Bringing A Biology-First Approach to Comprehensive Cancer Profiling

• Five years after the launch of Indiegene V1, the next generation expands to 2,206 genes with most comprehensive coverage of Hallmarks of Cancer, HRD scoring and 36 HRR genes profiling, and 299 fusions, individualised Tumour Mutation Burden (iTMB) score with percentile scoring

4baseCare, a precision oncology company building genomic and clinical intelligence for diverse populations, today announced the launch of TARGT Indiegene® V2, the next generation of its comprehensive genomic profiling (CGP) test for cancer biomarker testing.

The journey began on 15 August 2021, when 4baseCare launched the first Indiegene developed from insights generated through Indian tumour genomics and with the ambition of making comprehensive cancer profiling more accessible. Five years of continuous innovation, clinical experience and genomic insights have now led to Indiegene V2.

With 2,206 genes, V2 significantly expands the genomic breadth of the original panel. More importantly, it introduces a different way of looking at cancer.

Cancer is more than a mutation. Tumours are driven by interconnected biological processes that influence growth, survival, DNA repair, immune evasion and progression. TARGT Indiegene® V2 brings this perspective into CGP through genomic coverage mapped across the Hallmarks of Cancer.

Key capabilities include:

• 2,206 genes for broad genomic profiling
• Hallmarks of Cancer-led coverage to understand the biology driving tumour behaviour
• Immunotherapy biomarkers like MSI and individualised Tumour Mutation Burden (iTMB) score with percentile scoring. 
• HRD scoring and comprehensive coverage of 36 HRR genes. 
• CNVs and 299 clinically relevant fusions, among the most extensive fusion coverage available in commercial CGP assays

“Indiegene V2 is not simply a larger gene panel. It represents a shift from looking for individual biomarkers to understanding the biology behind cancer. As we take Indiegene to more patients and clinicians across global markets, our ambition remains the same, which is to make comprehensive, meaningful precision oncology accessible across diverse populations.” said Hitesh Goswami, Co-founder & CEO, 4baseCare

“Developed through 4baseCare’s experience in population-relevant oncology and now being taken to global markets, TARGT Indiegene® V2 represents the next chapter in our vision to build globally relevant precision-oncology solutions for diverse and historically underrepresented populations”, Kshitij Rishi, Co-Founder and COO, 4baseCare

About 4baseCare

Backed by Infosys and Illumina, 4baseCare is a precision oncology company working to make personalised cancer care more accessible, inclusive and data-driven. The company combines advanced genomic testing, population-relevant clinico-genomic datasets, real-world evidence and AI-powered analytics to support more informed cancer-care decisions. Headquartered in Bengaluru, 4baseCare is expanding its precision oncology footprint across India and international markets with advanced genomics labs in Dubai, Nepal and Philippines. 4baseCare OncoTwin, an AI-based Oncology Digital Twin platform was recently selected for MSKCC iHub program.

4baseCare Partners with Bio Valley to Build India’s Next-Gen Genomics Hub in Vizag

In a significant step towards building India's Next-Generation Genomics ecosystem, Bio Valley, 4baseCare and Define Bio (P) Ltd. (Biobank) have signed a Memorandum of Understanding (MoU) to establish a Center of Excellence (CoE) named BioSphere dedicated to Genomics and Next-Generation Sequencing (NGS) at Andhra Pradesh MedTech Zone (AMTZ), Vizag.

The CoE-BioSphere shall strengthen national genomic infrastructure by enabling early and accurate diagnostics, informed therapeutic decisions, and advanced personalized treatments. By generating large-scale datasets reflecting India’s genetic diversity, along with the integration of relevant global genomic datasets, the CoE–BioSphere will support the development of Diagnostics, Risk prediction models, and therapies aligned with Indian genomic variations while maintaining international scientific benchmarks and interoperability. It also fosters structured research collaborations among Clinicians, Academic Institutions, Industry partners, and data-based Start-ups while also serving as a platform to train the Next Generation of Scientists and Entrepreneurs in data-driven research and product development

At a national level, population-scale genomic insights will contribute to evidence-based public health policy and preventive strategies, enhancing accessibility, affordability, and the long-term impact on healthcare in India.

“This collaboration with Bio Valley, 4baseCare and Define Bio represents a significant step in strengthening India’s innovation-led Biotech ecosystem at AMTZ. By bringing together advanced genomics expertise, incubation support, and translational research capabilities, we aim to accelerate the development of impactful precision medicine solutions. Partnerships like these reinforce our commitment to nurturing cutting-edge healthcare innovation from Andhra Pradesh and enabling globally relevant breakthroughs from India." - said Hitesh Goswami, CEO & Co-founder of 4baseCare

The key highlight of the initiative is the creation of a dedicated incubation center within CoE–BioSphere to nurture genomics-based startups. The center shall support emerging companies with sequencing services, access to data, and mentorship for product development. The CoE–BioSphere shall be a burgeoning hub for Genomics-driven Healthcare and Biotechnology advancements at AMTZ

“Building India's Next-Generation Genomic Ecosystem: This strategic partnership advances data-driven precision Healthcare solutions and Genomic innovation, marking a major achievement for personalized Medical solutions in India.” said - Dr. K. Suseela Branham, CEO Bio Valley.

4baseCare Launches New Genomics Lab in Bengaluru, Unveils Global Cancer Diversity Atlas

4baseCare, a precision oncology company, inaugurated its new genomics laboratory in Mahadevapura, Bengaluru, as a part of its consistent efforts to advance access to precision oncology in India. The highlight of the launch event was the unveiling of Global Cancer Diversity Atlas (GCDA) aimed at addressing the genomics data gap that exists in cancer care.

The launch event was presided over by Mr. N. R. Narayana Murthy, Chairman, Infosys, who also unveiled the Global Cancer Diversity Atlas. In attendance were Ganapathy Subramaniam, Founding Managing Partner at Yali Capital, Rajan Anandan, Managing Director , Peak XV Partners, and founders of 4baseCare, Hitesh Goswami and Kshitij Rishi.

 

4baseCare’s new genomics lab in Bengaluru will offer advanced genomic testing solutions including comprehensive gene panels, whole exome sequencing, and transcriptome analysis. These tools will enable oncologists to delve deeper into the genetic makeup of tumors, offering personalized and more effective cancer treatment options.

The Global Cancer Diversity Atlas (GCDA) is a pioneering initiative by 4baseCare designed to address a critical gap in global cancer research: the lack of genomic data from diverse populations. While most cancer genomic datasets are dominated by Western populations, GCDA is built on real-world data from India and the Global South, including South Asia, Southeast Asia, the Middle East, Central Europe, and Latin America. GCDA is the world’s most inclusive cancer genomics dataset, transforming how we develop diagnostics, conduct research, and deliver cancer care so that every patient, everywhere, is truly seen and understood.

Commenting on the new lab and the unveiling of GCDA, Hitesh Goswami, CEO and Co-Founder, 4baseCare, said, “Our new genomics lab and the unveiling of the GCDA are driven by a single goal of creating better access to precision oncology. One of the key challenges in cancer care today is the lack of genomic data from Indian and Asian populations. This data gap has a significant impact on the effectiveness of cancer diagnostics and treatment strategies for under-represented communities.”

“At 4baseCare, we have firsthand seen the kind of real-world impact our genetic tests have had on cancer patients because of the right genomic data sets. Through our lab, we are creating an infrastructure to build population-specific genomic data at scale. And with GCDA, our aim is to close the diversity gap in cancer research that can change how cancer diagnosis and treatment is approached worldwide”, Hitesh added.

About 4baseCare

Founded in 2018 by Hitesh Goswami and Kshitij Rishi, 4baseCare has been a pioneer in launching unique solutions in cancer care to support oncologists match patients with the right targeted therapy based on biomarker identification. 4baseCare’s best-in-class genomic-based tests include #IndiaKaGenePanel, Indiegene which is the world's first Indian population specific cancer gene panel for biomarker testing.

4baseCare is an Illumina accelerator company, backed by Infosys Innovation fund. 4baseCare also secured 6 million in series A funding round from Yali Capital, is the first Asia/Pacific company to be selected for Illumina’s accelerator program in 2019. 4baseCare has also been awarded a 5 Million INR Biotechnology Ignition Grant (BIG), a flagship scheme of Biotechnology Industry Research Assistance Council (Biotechnology Industry Research Assistance Council (BIRAC), a Public Sector Undertaking the Department of Biotechnology, Government of India. Very recently,

4baseCare has expanded its global footprint by launching operations in Dubai by establishing a state-of-the-art genomics laboratory at Dubai Science Park, in collaboration with Innovate Life Sciences. The facility has recently earned CAP Accreditation. Strengthening its international presence, the company inaugurated a new lab in the Philippines in May 2025, in partnership with LINCs Philippines.

For more details, visit, https://4basecare.com/

AIIMS Jammu and 4baseCare Launches Centre for Advanced Genomics & Precision Medicine

The All India Institute of Medical Sciences (AIIMS) Jammu has officially initiated laboratory operations with the illumina NextSeq 2000 sequencing machine, at its newly established Centre for Advanced Genomics & Precision Medicine — marking a transformative step toward making affordable, precision-driven cancer care accessible to patients across India.

Inaugurating the state-of-the-art facility were key dignitaries, including Prof. (Dr) Shakti Kumar Gupta, Executive Director and CEO of AIIMS Jammu; Lt Gen Dr Sunil Kant, Dean Research and Medical Superintendent; Prof. Dr Meeta Gupta, Dean (Academics); Prof. Dr Shabab L Angurana, Associate Dean (Research); Mr. Shailender Slathia, Registrar; Dr. Poonam Sharma, Head, Department of Pathology; and Dr. Sudharshan, Vice President – Global Operations at 4baseCare.

Prof (Dr) Shakti Kumar Gupta, Executive Director and CEO, AIIMS Jammu, stated, “For every patient we treat, we are treating a mother, a father, a sister, or a brother. This partnership is our promise to every family who walks through our doors that we will do everything in our power to bring them the care they deserve.”

The Centre, developed in collaboration with 4baseCare, is equipped with advanced Next Generation Sequencing (NGS) technology, offering comprehensive genomic profiling for cancer patients. This powerful capability enables clinicians to design highly personalized, targeted treatment plans tailored to each patient’s unique molecular profile.

“By integrating cutting-edge genomic data with AI-powered diagnostics, the Centre is poised to significantly improve early disease detection, refine therapy choices, and minimize ineffective treatments — ultimately enhancing both patient outcomes and quality of life,” said Dr. Sudharshan Elangovan , Vice President – Global Operations at 4baseCare.

Traditionally, access to such advanced genomic testing has been prohibitively expensive for many patients. However, with this initiative, high-quality NGS-based tests will now be made available at affordable costs, paving the way for greater inclusivity in precision oncology across India.

Further solidifying its role as a national referral hub, the Centre will accept samples from patients and healthcare providers across the country, ensuring that cutting-edge molecular diagnostics are accessible, regardless of geographical barriers.

For more details, visit, https://4basecare.com/

Precision Oncology Startup 4baseCare Raises $2 Mn in Pre-Series A Round from A Consortium of Venture Capital Firms

BANGALORE, India, March 11, 2021 /PRNewswire/ -- 4baseCare, an Illumina Accelerator backed precision oncology start-up, has raised an investment of USD 2M, led by investors Mount Judi Ventures, growX Ventures, Season Two Ventures, First In Ventures and a few strategic angel investors. The investor group has a strong understanding of healthcare & technology and focuses on creating social impact through their investments.

Hitesh Goswami and Kshitij Rishi

4baseCare aims to make precision oncology a standard of care in Asia by increasing the utilization of genomic tests in oncology and is working towards developing a first of its kind, Indian population specific gene panel that will analyze a large number of genes for cancer-associated mutations to identify optimal treatment options leading to improved outcomes.

With an annual cancer burden of 1.5 M+ across the country, these genomic tests are available to very few patients who can afford such tests. This is because of the current available test which is primarily sourced from foreign companies and are exorbitantly priced. The need of the hour is the development of affordable and indigenous solutions which can benefit more patients.

4baseCare will utilize the funds for expansion of the genomic tests portfolio and for increasing their geographical presence across Asia. Additionally, it will also focus on strengthening its R&D and operations.

Hitesh Goswami CEO, 4baseCare says, "Access to advanced technology, which can help improve treatment and care should be for everyone. Our vision is to leverage on technology to develop affordable solutions to personalize patient care in Oncology".

Kshitij Rishi, COO 4baseCare says, "With this capital, we will be increasing the affordability of our genomic test portfolio through research and process efficiency. With our comprehensive solutions and global collaborations, we are confident that we will make precision medicine a standard of cancer care in our country".

Mr. Sherif Kottapurath, Managing Partner of MJV and Ex-CTO of Sun Microsystems says, "We are delighted that 4baseCare, with its innovative and life-critical suite in precision oncology, is the second investment by Mount Judi India Growth Fund in the healthcare vertical. We are happy that in this funding round, 4baseCare was able to attract a strong consortium of investors from India and USA, which will fuel its growth across and beyond India".

Manu Rikhye, Partner at growX Ventures said "Cancer is the second most common cause of death in India and 4baseCare is leading the charge to fight it. 4baseCare team is leveraging its deep expertise in genomics to enable timely cancer diagnosis, and help identify the most precise targeted therapies to significantly improve patient outcomes. We look forward to working with this exceptional founding team as they work towards making India healthier".

Sajan Pillai, CEO and Managing Partner of Season Two Ventures said, "Genomics and other data capabilities are now redefining life sciences. Their quest to make precision oncology more affordable and accessible contributes greatly to the growing biotech space in India & globally & we are extremely happy to support them in their journey."

About Mount Judi Ventures

Mount Judi Ventures (MJV), a boutique fund house founded by successful entrepreneurs and experienced professionals, was the lead investor of this round. It aims to invest in innovative Indian start-ups in the early growth stage across MedTech / Healthcare, EduTech, Digital / IoT, Food, and CleanTech, and offers equitable terms to both the investors and entrepreneurs.

About growX Ventures

growX is a B2B and DeepTech focused early-stage venture fund which works closely with investee firms at both strategic and operational levels to drive scale and success. Its investments are focused on pre-seed and seed stages across a wide range of sectors. growX has invested in 35 companies like Fynd, Locus, Mad Street Den, Pixxel, Progcap, Wellthy, and Zipolan, among others.

About Season Two Ventures

Season Two Ventures is an early-stage venture fund based in Southern California investing in B2B companies in both the US and India. The fund seeks to generate value by identifying large scale problems, finding companies to solve those problems, and creating a pipeline of customers upon investment. The current fund focuses on four industry verticals: healthcare, fintech, supply chain, and energy tech.

About 4baseCare

4baseCare is engaged in the development of affordable and accessible precision oncology solutions, using advanced genomics and next-generation digital health technology, to personalize patient care in oncology.

With their presence in India and Singapore, 4baseCare is the first Asian healthcare organization backed by Illumina (the Global Genomics leader) through their Illumina Accelerator program.

4baseCare has also been selected for the 2nd Cohort of the AISEA accelerator (Sponsored by Department of Science & Technology, Govt. of India).

Website: https://4basecare.com
LinkedIn: https://www.linkedin.com/company/4basecare-genomics-private-limited/
Twitter: https://twitter.com/4basecare

Media Contact : SHUBHAM SHARMA, shubham@4basecare.com, 9886787900, Marketing Manager, 4baseCare